Diagnostic Value of Anti‐deamidated Gliadin Peptide IgG Antibodies for Celiac Disease in Children and IgA‐deficient Patients

Mozo, Lourdes; Gómez, Jesús María Fernández; Escanlar, Esther; Bousoño, Carlos; Gutiérrez, Carmen

doi:10.1097/mpg.0b013e31824703c7

Cited by 41 publications

(28 citation statements)

References 33 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…What is the effectiveness of screening vs not screening for celiac disease in asymptomatic adults, adolescents, or children on morbidity, mortality, or quality of life? 20,23,39 Sensitivities and specificities were generally similar across age groups, with the exception of 1 study that reported specificity of 26% among persons 18 years or younger for the DGP IgA test. 20 Sensitivities were somewhat lower for adults than for children, but differences were slight.…”

Section: Key Questionsmentioning

confidence: 94%

Screening for Celiac Disease

Chou

Bougatsos

Blazina

et al. 2017

JAMA

View full text Add to dashboard Cite

IMPORTANCE Silent or subclinical celiac disease may result in potentially avoidable adverse health consequences. OBJECTIVE To review the evidence on benefits and harms of screening for celiac disease in asymptomatic adults, adolescents, and children 3 years and older for the US Preventive Services Task Force. DATA SOURCES Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews, searched to June 14, 2016. STUDY SELECTION Randomized clinical trials and cohort or case-control studies on clinical benefits and harms of screening vs no screening for celiac disease or treatment vs no treatment for screen-detected celiac disease; studies on diagnostic accuracy of serologic tests for celiac disease. DATA EXTRACTION AND SYNTHESIS One investigator abstracted data, a second checked data for accuracy, and 2 investigators independently assessed study quality using predefined criteria. MAIN OUTCOMES AND MEASURES Cancer incidence, gastrointestinal outcomes, psychological outcomes, child growth outcomes, health outcomes resulting from nutritional deficiencies, quality of life, mortality, and harms of screening. No meta-analytic pooling was done. RESULTS One systematic review and 3 primary studies met inclusion criteria. No trials of screening for celiac disease were identified. One recent, good-quality systematic review of 56 original studies and 12 previous systematic reviews (sample sizes of primary studies ranging from 62 to more than 12 000 participants) found IgA tissue transglutaminase was associated with high accuracy (sensitivity and specificity both >90%) for diagnosing celiac disease. IgA endomysial antibodies tests were associated with high specificity. Only 2 studies of serologic tests for celiac disease involving 62 and 158 patients were conducted in asymptomatic populations and reported lower sensitivity (57% and 71%). One fair-quality, small (n = 40) Finnish treatment trial of asymptomatic adults with screen-detected celiac disease based on positive serologic findings found initiation of a gluten-free diet associated with small improvement in gastrointestinal symptoms compared with no gluten-free diet (difference less than 1 point on a scale of 1 to 7) at 1 year, with no differences on most measures of quality of life. No withdrawals due to adverse events occurred during the trial; no other harms were reported. No studies were identified that addressed the other outcomes. CONCLUSIONS AND RELEVANCE Although some evidence was found regarding diagnostic accuracy of tests for celiac disease, little or no evidence was identified to inform most of the key questions related to benefits and harms of screening for celiac disease in asymptomatic individuals. More research is needed to understand the effectiveness of screening and treatment for celiac disease, accuracy of screening tests in asymptomatic persons, and optimal screening strategies.

show abstract

Section: Key Questionsmentioning

confidence: 94%

Screening for Celiac Disease

Chou

Bougatsos

Blazina

et al. 2017

JAMA

View full text Add to dashboard Cite

show abstract

“…At the moment, anti-TG2 antibodies form the most specific and sensitive marker for active celiac disease and their detection is the preferred diagnostic test in most cases [54,55]. New tests to detect IgG anti-gluten antibodies using synthetic deamidated gliadin peptides as substrates perform almost as well as the IgA anti-TG2 test [47] and have been shown to be especially useful in the diagnoses of infants and IgA-deficient patients [56].…”

Section: Antibody Response In Celiac Diseasementioning

confidence: 98%

T-cell and B-cell immunity in celiac disease

Pré

Sollid

2015

Best Practice & Research Clinical Gastroenterology

View full text Add to dashboard Cite

“…Peptide gliadindetermination is a new technique for IgA deficient patients [30] [31]. CD is closely linked to the HLA region; the highest titles are set for the HLADQ2, while the remaining titles are for the DQ8 (Figure 1).…”

Section: Diagnosis Testmentioning

confidence: 99%

A Brief Review on Neurologic and Psychiatric Manifestations of Celiac Disease

Basilio¹,

Nilson²,

Martha³

2016

WJNS

View full text Add to dashboard Cite

Celiac Disease (CD) is a rare autoimmune disorder with manifestations at different levels including the central nervous system. The disease develops as a consequence of intolerance to gluten on individuals with genetic susceptibility. It originates as a result of the interaction between genetic and environmental factors, on individuals predisposed, through a faulty immune system response to prolamin derived peptides. Usually the diagnosis is established based on clinical suspicion, either within a suspicious family group context or in patients with suggestive manifestations of this disease.

show abstract

Diagnostic Value of Anti‐deamidated Gliadin Peptide IgG Antibodies for Celiac Disease in Children and IgA‐deficient Patients

Cited by 41 publications

References 33 publications

Screening for Celiac Disease

Screening for Celiac Disease

T-cell and B-cell immunity in celiac disease

A Brief Review on Neurologic and Psychiatric Manifestations of Celiac Disease

Contact Info

Product

Resources

About